Evidence map›Paper›PMID 41428057›Full record

ArticleSurgery today2026

Identification of the novel therapeutic target gene SLC12A9, which determines the prognosis of patients with colorectal cancer.

Yusuke Yonemura, Takashi Ofuchi, Takafumi Nakano, Satoshi Higuchi, Koto Kawata, Tomohiko Ikehara, Kazuki Omachi, Akinori Tsujimoto, Kosuke Hirose, Shohei Shibuta and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yusuke YonemuraDepartment of Surgery, Kyushu University Beppu Hospital, Tsurumihara, 4546, 874-0838, Beppu, Japan.
Takashi Ofuchi *Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara, 4546, 874-0838, Beppu, Japan.
Takafumi Nakano *Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara, 4546, 874-0838, Beppu, Japan.
Satoshi Higuchi *Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara, 4546, 874-0838, Beppu, Japan.
Koto KawataDepartment of Surgery, Kyushu University Beppu Hospital, Tsurumihara, 4546, 874-0838, Beppu, Japan.
Tomohiko IkeharaDepartment of Surgery, Kyushu University Beppu Hospital, Tsurumihara, 4546, 874-0838, Beppu, Japan.
Kazuki OmachiDepartment of Surgery, Kyushu University Beppu Hospital, Tsurumihara, 4546, 874-0838, Beppu, Japan.
Akinori TsujimotoDepartment of Surgery, Kyushu University Beppu Hospital, Tsurumihara, 4546, 874-0838, Beppu, Japan.
Kosuke HiroseDepartment of Surgery, Kyushu University Beppu Hospital, Tsurumihara, 4546, 874-0838, Beppu, Japan.
Shohei ShibutaDepartment of Surgery, Kyushu University Beppu Hospital, Tsurumihara, 4546, 874-0838, Beppu, Japan.
Yuki AndoDepartment of Surgery, Kyushu University Beppu Hospital, Tsurumihara, 4546, 874-0838, Beppu, Japan.
Qingjiang HuDepartment of Surgery, Kyushu University Beppu Hospital, Tsurumihara, 4546, 874-0838, Beppu, Japan.
Hajime OtsuDepartment of Surgery, Kyushu University Beppu Hospital, Tsurumihara, 4546, 874-0838, Beppu, Japan.
Tomoharu Yoshizumi *Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara, 4546, 874-0838, Beppu, Japan.
Koshi Mimori *Department of Surgery, Kyushu University Beppu Hospital, Tsurumihara, 4546, 874-0838, Beppu, Japan. mimori.koshi.791@m.kyushu-u.ac.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFeasible therapeutic targets need to be identified to overcome tumor heterogeneity and ameliorate therapeutic resistance. We explored the identification of oncogenes on Ch.7q, which is amplified ubiquitously in colorectal cancer (CRC). In this study, we focused on SLC12A9, which encodes a channel protein that regulates ion concentration inside and outside of the cell. MATERIALS AND

methodsExpression and survival analyses of SLC12A9 were performed using reverse transcription quantitative polymerase chain reaction, The Cancer Genome Atlas dataset, and immunohistochemistry. A gene set enrichment analysis (GSEA) was performed to elucidate the correlation between SLC12A9 and gene sets associated with tumor progression. Subsequently, an in vitro proliferation assay was performed using SLC12A9-knockdown CRC cells.

resultsSLC12A9 was highly expressed in tumor cells, and its high expression was associated with a poor prognosis. The GSEA revealed an association with mTORC1 signaling. In the colony formation assay, SLC12A9 knockdown by siRNA suppressed the proliferative capacity of CRC cells. Public single-cell RNA sequencing data have revealed that SLC12A9 is derived from malignant epithelial cells in CRC tissues.

conclusionOur results suggest that abundant SLC12A9 expression is associated with a poor prognosis due to the devastating growth of CRC cells, in part via the mTORC1 signaling pathway.

Indexed as

Colorectal NeoplasmsGene ExpressionMolecular Targeted TherapySolute Carrier Family 12Biomarkers, TumorCell ProliferationGene Expression Regulation, NeoplasticGene Knockdown TechniquesHumansMechanistic Target of Rapamycin Complex 1PrognosisSignal TransductionBiomarkers, TumorMechanistic Target of Rapamycin Complex 1Solute Carrier Family 12Colorectal cancer biomarkerIon transport and tumorigenesisMTORC1 signaling pathwayTherapeutic target

Identifiers

PMID41428057

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.